Entering text into the input field will update the search result below

Cyclo Therapeutics reports Q3 results

Nov. 11, 2022 8:16 AM ETCyclo Therapeutics, Inc. (CYTH) StockBy: Niloofer Shaikh, SA News Editor
  • Cyclo Therapeutics press release (NASDAQ:CYTH): Q3 net loss of $4.2M.
  • The company expects research and development to further increase in 2022 as we continue to seek regulatory approval for the use of Trappsol® Cyclo™ in the treatment of NPC and Alzheimer’s disease.
  • The company ended the quarter with approximately $4.3M of cash.
  • Shares +7.5% PM.

Recommended For You

More Trending News

About CYTH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CYTH--
Cyclo Therapeutics, Inc.